Agios Pharmaceuticals AGIO Contract with Customer, Asset, after Allowance for Credit Loss
Contract with Customer, Asset, after Allowance for Credit Loss at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetNet.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's contract with customer, asset, after allowance for credit loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Agios Pharmaceuticals's contract with customer, asset, after allowance for credit loss?
- Agios Pharmaceuticals (AGIO) reported contract with customer, asset, after allowance for credit loss of $16.13M in Q1 2026.
- How has Agios Pharmaceuticals's contract with customer, asset, after allowance for credit loss changed year-over-year?
- Agios Pharmaceuticals's contract with customer, asset, after allowance for credit loss increased by 382.4% year-over-year, from $3.34M to $16.13M.